Castle Biosciences, Inc. (CSTL)
| Market Cap | 1.09B +63.5% |
| Revenue (ttm) | 357.28M +3.2% |
| Net Income | -19.42M |
| EPS | -0.65 |
| Shares Out | 30.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 39,696 |
| Open | 35.45 |
| Previous Close | 35.56 |
| Day's Range | 35.10 - 36.05 |
| 52-Week Range | 17.72 - 44.28 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 45.11 (+26.25%) |
| Est. Earnings | Nov 2, 2026 |
About CSTL
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price target is $45.11, which is an increase of 26.25% from the latest price.
News
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
Data show patients with low-risk DecisionDx-Melanoma i31-SLNB results had sentinel lymph node (SLN) positivity below 5% when biopsied, and eligible patients who avoided SLNB had five-year recurrence-f...
Castle Biosciences: Study shows TissueCypher test changed management
Castle Biosciences (CSTL) announced the publication of a study showing that its TissueCypher Barrett’s Esophagus Test helped guide risk-aligned management decisions for patients with non-dysplastic Ba...
New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
FRIENDSWOOD, Texas, Sept. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication...
New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
Study data showed more than half of patients who used targeted systemic therapies modified treatment due to lack of efficacy Among patients surveyed in the study, 94% of those open to a new systemic t...
Castle Biosciences to open new laboratory facility in Scottsdale, Arizona
Castle Biosciences (CSTL) announced the opening of its new laboratory and office facility in Scottsdale, Arizona. The company will commemorate the milestone with a grand opening celebration at the new...
Castle Biosciences to Open New Laboratory Facility in Scottsdale
New 55,000-square-foot facility expands Castle's operational footprint in Arizona to support growing test volumes and long-term growth FRIENDSWOOD, Texas, Sept. 22, 2026 /PRNewswire/ -- Castle Bioscie...
Castle Biosciences management to meet with BTIG
Meeting to be held in the Midwest on September 30 and October 1 hosted by BTIG.
Castle Biosciences Transcript: 2026 Global Healthcare Conference
Strong Q2 growth was highlighted by a 63% YoY increase in TissueCypher volumes and robust gross margins, supporting ongoing R&D. Market penetration for Barrett's esophagus testing is expanding, with workflow integration and sales force productivity expected to drive further gains. AI initiatives and new product launches in dermatology are positioned to contribute significantly to future revenue.
Castle Biosciences’ TissueCypher shows improvement in Barrett’s esophagus
Castle Biosciences (CSTL) announced the publication of a new decision modeling study showing that the TissueCypher Barrett’s Esophagus test – TSP-9 – can help better align Barrett’s esophagus, or BE,…
New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus
Decision modeling study shows use of TissueCypher can nearly double appropriate escalation of care for patients with non-dysplastic Barrett's esophagus who later progress to cancer, while substantiall...
Castle Biosciences publishes DecisionDx-SCC test result study in JAAD
Castle Biosciences (CSTL) announced the publication of a multi-center study in the Journal of the American Academy of Dermatology, or JAAD, validating the integrated DecisionDx-SCC test result for pat...
JAAD Publication Shows Improved Performance of DecisionDx®-SCC
DecisionDx-SCC shows enhanced performance with the integration of select clinicopathologic risk factors, providing a more precise result to support risk-aligned patient management DecisionDx-SCC's Cla...
SciBase receives additional order from Castle Biosciences, advancing the collaboration
STOCKHOLM, Sept. 8, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has received an a...
Castle Biosciences to Participate in Upcoming Investor Conferences
FRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executi...
Castle Biosciences approved for dual listing on Nasdaq Texas
Castle Biosciences (CSTL) announced that it has been approved to have its common stock dually listed on Nasdaq Texas, a new exchange headquartered in Dallas. Castle will maintain its primary…
Castle Biosciences Approved for Dual Listing on Nasdaq Texas
FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been...
Castle Biosciences Transcript: Canaccord Genuity's 46th Annual Growth Conference
Strong growth in melanoma and GI cancer testing is driving raised guidance, with continued physician education and expanded sales force supporting further penetration. New product launches and reimbursement milestones are expected to contribute to revenue growth, with adjusted EBITDA projected to remain positive through 2027.
Castle Biosciences price target raised to $44 from $40 at BTIG
BTIG raised the firm’s price target on Castle Biosciences (CSTL) to $44 from $40 and keeps a Buy rating on the shares after “a strong Q2 beat” and another guidance…
Castle Biosciences price target raised to $44 from $40 at BTIG
BTIG raised the firm’s price target on Castle Biosciences (CSTL) to $44 from $40 and keeps a Buy rating on the shares. The company delivered a strong Q2 beat on…
Castle Biosciences price target raised to $57 from $52 at Lake Street
Lake Street raised the firm’s price target on Castle Biosciences (CSTL) to $57 from $52 and keeps a Buy rating on the shares following a Q2 “blowout” accompanied by a…
Castle Biosciences price target lowered to $36 from $43 at Baird
Baird lowered the firm’s price target on Castle Biosciences (CSTL) to $36 from $43 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.
Castle Biosciences Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 20% year-over-year to $103.5 million, driven by strong test volume growth in core products. Full-year revenue guidance was raised to $365–$375 million, with positive adjusted EBITDA expected for 2026. Robust cash reserves support ongoing investments in growth and pipeline expansion.
Castle Biosciences Earnings release: Q2 2026
Castle Biosciences released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Castle Biosciences Quarterly report: Q2 2026
Castle Biosciences has published its Q2 2026 quarterly earnings report on July 30, 2026.
Castle Biosciences Slides: Q2 2026
Castle Biosciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.